Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Retained Earnings (2021 - 2025)

Stoke Therapeutics has reported Retained Earnings over the past 5 years, most recently at $543000.0 for Q4 2025.

  • For Q4 2025, Retained Earnings rose 459.6% year-over-year to $543000.0; the TTM value through Dec 2025 reached $543000.0, up 459.6%, while the annual FY2025 figure was $543000.0, 459.6% up from the prior year.
  • Retained Earnings for Q4 2025 was $543000.0 at Stoke Therapeutics, up from -$439.8 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $543000.0 in Q4 2025 and troughed at -$480.3 million in Q3 2024.
  • A 5-year average of -$184.1 million and a median of -$1.7 million in 2022 define the central range for Retained Earnings.
  • On a YoY basis, Retained Earnings climbed as much as 459.6% in 2025 and fell as far as 2676126.67% in 2025.
  • Year by year, Retained Earnings stood at -$168000.0 in 2021, then tumbled by 599.4% to -$1.2 million in 2022, then crashed by 34099.91% to -$401.8 million in 2023, then soared by 99.96% to -$151000.0 in 2024, then surged by 459.6% to $543000.0 in 2025.
  • Business Quant data shows Retained Earnings for STOK at $543000.0 in Q4 2025, -$439.8 million in Q3 2025, and -$401.4 million in Q2 2025.